Modern principles of treatment of inflammatory bowel diseases
https://doi.org/10.21518/2079-701X-2019-3-6-7
Abstract
Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, in terms of severity of course, frequency of complications and lethality are among the main positions in the structure of diseases of the digestive system. With a question about modern ways of solving this important problem we addressed to Academician of the Russian Academy of Sciences, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology of A.I. Evdokimov Moscow State Medical University, Doctor of Medical Sciences, Professor Igor Veniaminovich Maev.
References
1. Инструкция по медицинскому применению лекарственного препарата Энтивио® РУ №ЛП-003697.
2. Feagan B.G. et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369:699-710.
3. Loftus E.V., et al. Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. J Crohn’s Colitis. 2017 Feb;11(Suppl 1):S182-S183.
4. Sandborn W.J., et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2013;369:711-21.
5. Kaser A., et al. Long-term effectiveness and safety of vedolizumab in patients with Crohn’s disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI Open-Label Extension study. Gut. 2017;66(Suppl 2):A1–A288.
6. Colombel J.F., et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–851.
Review
For citations:
Modern principles of treatment of inflammatory bowel diseases. Meditsinskiy sovet = Medical Council. 2019;(3):6-7. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-6-7
Views:
661
Email this article 